From biology to therapy: current standards and emerging strategies in pleural mesothelioma
Frontiers in Oncology · 26.03.2026 · 16
DOI: 10.3389/fonc.2026.1778121 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 26.03.2026. Verfasst von J H L T van Genugten und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital/Netherlands cancer Institute (AVL-NKI) - Netherlands Cancer Institute/Antoni van Lee…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pleural mesothelioma (PM) is an aggressive malignancy with limited therapeutic options and poor long-term prognosis. Platinum-based chemotherapy has been the standard-of-care for most patients for decades. While the decoding of the genomic alterations in PM has triggered renewed interest in mesothelioma biology and targeted therapies, these have yet to reach clinical practice. The recent introduction of dual immune checkpoint blockade (ICB) with nivolumab plus ipilimumab has marked the first major advance in PM treatment for decades, yet, many patients do not respond to these drugs and durable long-term responses remain rare. A range of alternative treatment modalities are currently under clinical investigation in PM, including antibody-drug conjugates, bi-specific antibodies, chimeric antigen receptor T-cells, cancer vaccines, and oncolytic viruses. Here we review recent progress in the understanding of PM biology and evaluate relevant phase I-III clinical trials aimed at improving treatment for this disease. We also highlight ongoing and future clinical trials with promising candidates for PM therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital/Netherlands cancer Institute (AVL-NKI) - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
- Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands.
Zitieren
APA
van Genugten, J. H. L. T., de Gooijer, C. J., & Baas, P. (2026). From biology to therapy: current standards and emerging strategies in pleural mesothelioma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1778121
Vancouver
van Genugten JHLT, de Gooijer CJ, Baas P. From biology to therapy: current standards and emerging strategies in pleural mesothelioma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1778121
BibTeX
@article{vanGenugten2026,
author = {van Genugten, J H L T and de Gooijer, C J and Baas, Paul},
title = {From biology to therapy: current standards and emerging strategies in pleural mesothelioma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1778121}
}
EUVIMED